Outsmarting cancer, together

Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.

Learn more

Our Vision

Omico will improve outcomes for Australians with cancer by accelerating the use of precision oncology as a research-led model of care, growing the clinical trials industry and modernising the Australian healthcare system.

Our Values

Innovation, Collaboration, and Hope

Our Mission

MoST Clinical Trials

MoST Substudies

Recent News

Pancreatic cancer program

Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.

Read more

2020 Masterclass Publications and webinar recordings

View the "Demystifying the Molecular Tumour Board" Masterclass publication and webinar recordings

Read more

ASPiRATION study - first patient enrolled

The first patient has been enrolled into the ‘ASPiRATION’ Study. The study is looking at the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC) in newly diagnosed metastatic, non-squamous, non-small cell lung cancer patients.

Read more
More news

Interested in knowing more?

Get in touch